News Releases

 

BioSante Pharmaceuticals to Host Conference Call to Announce LibiGel® Special Protocol Assessment (SPA)

Lincolnshire, Illinois (January 28, 2008) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it will host a conference call tomorrow, Tuesday, January 29, 2008 at 11:00 a.m. ET to announce and discuss the LibiGel (testosterone gel) SPA received from the U.S. Food and Drug Administration (FDA) for the development of LibiGel in the treatment of female sexual dysfunction.

Details for the call are provided below.

  • When – Tuesday, January 29, 2008 at 11:00 a.m. ET
  • Live Domestic and Canada call in: – 877-407- 0778
  • Live international call in – 201-689-8565
  • Website for listen only http://www.vcall.com/IC/CEPage.asp?ID=125262
  • Replay Domestic and Canada – 877-660- 6853
  • Replay International – 201-612-7
  • 24 hour replay, web access http://www.vcall.com/IC/CEPage.asp?ID=125262
  • Replay pass codes, (both required for playback)
  • Account # – 286 Conference ID – 271970

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD) and Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to- severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante’s licensee.

Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz

###

For more information please contact:

For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220
azachary@harrisdmckinney.com